Therapeutic potential of TAS-115 in 3D breast cancer models

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. TAS-115, a multi-receptor tyrosine kinase inhibitor, has not previously been evaluated in TNBC. Here, we investigated its therapeutic effects alone and in combination with doxorubicin (DOXO), using three-dimensional heterotypic spheroid models, including free-standing, bioprinted static, and perfused systems. TAS-115 significantly reduced cell proliferation and viability, enhanced apoptosis, and suppressed c-mesenchymal-epithelial transition/hepatocyte growth factor and PI3K/Akt/mTOR signaling. Combined treatment with DOXO further amplified these effects. In perfused bioprinted models, TAS-115 markedly inhibited tumor cell migration, highlighting its potential to limit metastatic behavior. These findings identify TAS-115 as a promising therapeutic strategy for TNBC, either as a monotherapy or in combination with chemotherapy.
Funding Information
  • National Institute of Biomedical Imaging and Bioengineering (R01EB034566)
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (2023/11239-6)
  • Türkiye Bilimsel ve Teknolojik Araçtirma Kurumu (2214-A-2022/2)

This publication has 36 references indexed in Scilit: